Moderna's stock has spent nearly two years as a symbol of mRNA technology's fall from pandemic-era grace, sliding from its 2021 peak amid collapsing COVID-19 vaccine demand and mounting political skepticism toward the platform itself. On Wednesday, August 19, that stock had its best trading day in company history, surging as much as 177%, after Moderna and Merck announced their personalized mRNA cancer vaccine had succeeded in a large, late-stage melanoma trial.

The numbers behind the rally

Moderna shares closed up 177% on Wednesday, according to CNBC, after touching an intraday high near $163 during the session. Merck, whose far larger size limited the percentage move even as the news moved its stock meaningfully in absolute terms, closed up 12.6%. That size disparity explains the dramatically different percentage reactions: Merck entered Wednesday with a market capitalization of roughly $333 billion, while Moderna's stood at approximately $25 billion, meaning the same piece of news that added tens of billions in value to Merck effectively multiplied Moderna's own market value several times over in a single session.

TD Cowen analysts captured the trial's significance in blunt terms in a note to investors: "This is a landmark moment. We view the result as a significant validation of the platform." That framing, treating the result as validation for mRNA technology broadly rather than simply good news for one specific cancer treatment, helps explain why the market reaction proved so outsized relative to what a single trial result for one cancer type might ordinarily produce.

What the trial actually tested and found

The Phase 3 trial, known as INTerpath-001, enrolled more than 1,137 patients with high-risk or advanced melanoma whose detectable cancer had been completely removed through surgery. Researchers randomized patients roughly 2-to-1 to receive either the combination treatment, Moderna's mRNA-based vaccine called intismeran autogene alongside Merck's immunotherapy drug Keytruda, or Keytruda alone, the existing standard treatment used to help prevent melanoma recurrence following surgery.

The combination regimen met its primary study goal, significantly extending the time patients lived without their melanoma returning compared to the Keytruda-only control group. It also met a key secondary endpoint, extending the time before melanoma spread to other parts of the body. According to BioSpace's detailed trial coverage, the vaccine is also known by its earlier development names V940 and mRNA-4157, names that will be familiar to investors who tracked the drug's promising but less definitive earlier-stage results.

Why this specific vaccine works differently than existing shots

Intismeran autogene is described as a personalized cancer vaccine, built individually from a sample of each patient's own tumor tissue rather than manufactured as a single standardized product for all patients. The vaccine is specifically designed to teach a patient's immune system to recognize and attack the unique genetic mutations present in their own cancer cells, an approach fundamentally different from either a preventive vaccine designed to stop infection before it starts, or a standard cancer drug designed to work identically across every patient regardless of their tumor's specific genetic makeup.

Dr. Georgina Long, the trial's principal investigator, medical director of Melanoma Institute Australia, and chair of melanoma medical oncology and translational research at the University of Sydney, described the result in terms that echo TD Cowen's investor-facing assessment. "Today's results represent a landmark moment for adjuvant melanoma treatment," Long said. "Intismeran in combination with pembrolizumab has the potential to establish a new treatment paradigm in the adjuvant melanoma setting, helping patients remain cancer-free for longer." Pembrolizumab is Keytruda's generic name.

A treatment that could reach patients as soon as next year

Moderna President Stephen Hoge offered investors and patients a specific, near-term timeline in an interview following the announcement, saying thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine. That timeline reflects both the strength of the trial's interim results and the regulatory pathway available for treatments addressing serious, life-threatening cancers with limited existing options, which the FDA has historically moved through more quickly than standard drug approval timelines.

Hoge also addressed how the treatment's safety profile compared to existing options, telling reporters the combination's safety data remained consistent with earlier-stage studies and showed no new safety concerns, while suggesting the approach might allow doctors to treat earlier-stage cancers more aggressively than prior treatment options that carried greater toxicity to the body.

The disease this treatment specifically targets

Melanoma remains one of the deadlier forms of skin cancer, with more than 8,500 people in the United States expected to die from the disease this year according to figures cited in coverage of Wednesday's announcement. The trial specifically targeted patients with cutaneous melanoma at stages IIB through IV, following complete surgical removal of their detectable tumors, a category of patients who remain at meaningful risk of recurrence even after successful surgery and for whom Keytruda alone has represented the existing standard of care.

Dr. Kah Poh Loh's colleague at the trial, referred to in Fortune's coverage simply by surname Li, framed the broader clinical logic behind targeting patients at this specific point in their treatment: "By intervening earlier in the course of disease, when many cancers are considered most treatable, the goal of adjuvant therapy given after surgery is to increase the possibility of cure for more patients. We believe individualized neoantigen therapies have the potential to redefine how patients with completely resected stage IIB-IV melanoma are treated."

A rally that lifted the broader mRNA sector, not just Moderna

Wednesday's stock reaction extended beyond Moderna and Merck themselves. According to Axios, Wednesday's result may help lift what the outlet described as "the bigger cloud hanging over the technology," referring to the broader skepticism mRNA-based medicine has faced since the end of the pandemic vaccine boom, skepticism that has been compounded throughout 2026 by public criticism of mRNA vaccine technology from federal health officials. A successful Phase 3 result for an entirely different application of mRNA technology, cancer treatment rather than infectious disease prevention, offers the platform's supporters concrete evidence that mRNA's therapeutic potential extends meaningfully beyond the vaccine applications that first brought it to public attention.

What happens next for the treatment and the companies pursuing it

Moderna and Merck are continuing to test the same underlying mRNA-plus-Keytruda combination approach against other cancer types, including lung cancer, though the melanoma studies represent the furthest along in the companies' broader oncology development pipeline according to Yahoo Finance's reporting. That broader pipeline matters considerably for how investors are likely to value both companies going forward, since a successful mechanism validated in one cancer type doesn't automatically guarantee success against a biologically different disease, but it does give considerably more credibility to the companies' ongoing trials in those other indications than existed before Wednesday's melanoma results were announced.

For Moderna specifically, entering Wednesday's trading session already up 113% for the year on anticipation of exactly this trial result, the actual data landing as strongly as it did represents a rare case where a stock's speculative run-up into a binary clinical trial event was ultimately validated rather than punished by the market, a pattern that stands in notable contrast to how frequently biotech stocks tend to sell off sharply even on genuinely positive trial results that simply fail to exceed an already elevated set of investor expectations.

---

*Sources cited in this article include Moderna and Merck's official joint press release dated August 19, 2026, and reporting from CNBC, CNN, Bloomberg, Fortune, Axios, BioSpace, and CBS News covering the trial results and subsequent market reaction. All figures reflect reporting available as of August 19, 2026.*